VivoSeq
Oncology

Oral Squamous Cell Carcinoma

34

Pipeline Programs↗

12

Active Trials↗

19

Companies Involved↗

Oral Squamous Cell Carcinoma is a moderately active landscape with 34 programs across 19 companies. The most active players are AstraZeneca, Teva, LaNova Medicines Zhejiang Co., Ltd.. 3 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 1Teva logo

Teva

1 program

Phase 1L

LaNova Medicines Zhejiang Co., Ltd.

1 program

Phase 1A

Avyxa

2 programs

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical1

Pembrolizumab

Merck & Co.

Phase 15

Tremelimumab

AstraZeneca

Paclitaxel

Teva

Durvalumab

AstraZeneca

Apatinib

LaNova Medicines Zhejiang Co., Ltd.

Paclitaxcel

Shanghai Jiao Tong University School of Medicine

Phase 219

Camrelizumab

Sun Yat-sen University

Metformin Hydrochloride

Boehringer Ingelheim

Celecoxib

Philadelphia Eye Associates

Adebrelimab

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Toripalimab

Coherus Oncology, Inc.

Phase 36

Melatonin

Neurim Pharmaceuticals Ltd.

Alfacalcidol

Roche

TPF Experimental

Shanghai Jiao Tong University School of Medicine

Camrelizumab Plus TP

Hospital of Stomatology, Wuhan University

PRV111 (cisplatin Transmucosal System)

Privo Technologies

Approved3

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Imiquimod

Bausch Health Americas, Inc.

Metformin

EMD Serono

Analysis

Modality Breakdown

69%

Small molecule

29 of 42 classified programs — the dominant modality here.

31%ALL OTHERSMonoclonal antibody1229%Cell therapy12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.

Analysis

Trial Status

28

clinical trials

Recruiting10 · 36%
Completed9 · 32%
Unknown status7 · 25%
Active, not recruiting1 · 4%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

28 trials

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma
Recruiting·HHospital of Stomatology, Wuhan University·Phase 2·NCT06277791·35 enrolled
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
Recruiting·ZZhongnan Hospital·N/A·NCT05030597·100 enrolled
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
Recruiting·HHospital of Stomatology, Wuhan University·Phase 3·NCT05798793·309 enrolled
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
Recruiting·WWeijia Fang, MD·Phase 2·NCT05862168·30 enrolled
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02290145·48 enrolled
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06130332·40 enrolled
Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma
Recruiting·—·Phase 2/3·NCT05893888·40 enrolled
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
Recruiting·QQunxing Li,MD·Phase 3·NCT07371611·104 enrolled
Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial
Recruiting·—·Phase 2·NCT07007364·30 enrolled
Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06470217·116 enrolled
Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）
Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07267286·60 enrolled
Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07137858·70 enrolled
Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
Completed·HHospital of Stomatology, Wuhan University·Phase 2·NCT04649476·68 enrolled
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Completed·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT04473716·20 enrolled
TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Completed·SShanghai Jiao Tong University School of Medicine·Phase 2/3·NCT01542931·256 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)